Northwest Biotherapeutics Valuation Multiples

Northwest Biotherapeutics Overview

About Northwest Biotherapeutics

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

Founded

1998

HQ

Employees

25

Website

nwbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $1M

EBITDA: ($74M)

EV

$420M

Valuation Multiples

Multiples.vc

Start free trial

Northwest Biotherapeutics Financials

Northwest Biotherapeutics reported last fiscal year revenue of $1M and negative EBITDA of ($74M).

In the same fiscal year, Northwest Biotherapeutics generated ($74M) in EBITDA losses and had net loss of ($84M).

Northwest Biotherapeutics P&L

In the most recent fiscal year, Northwest Biotherapeutics reported revenue of $1M and EBITDA of ($74M).

Northwest Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Northwest Biotherapeutics Stock Performance

Northwest Biotherapeutics has current market cap of $347M, and enterprise value of $420M.

Northwest Biotherapeutics' stock price is $0.23.

Northwest Biotherapeutics Valuation Multiples

Northwest Biotherapeutics trades at 303.8x EV/Revenue multiple, and (5.7x) EV/EBITDA.

Northwest Biotherapeutics Financial Valuation Multiples

As of March 19, 2026, Northwest Biotherapeutics has market cap of $347M and EV of $420M.

Equity research analysts estimate Northwest Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Northwest Biotherapeutics has a P/E ratio of (4.1x).

Northwest Biotherapeutics Margins & Growth Rates

Northwest Biotherapeutics' revenue in the last fiscal year declined by (29%).

Northwest Biotherapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Northwest Biotherapeutics M&A Activity

Northwest Biotherapeutics acquired XXX companies to date.

Last acquisition by Northwest Biotherapeutics was on XXXXXXXX, XXXXX. Northwest Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Northwest Biotherapeutics Investment Activity

Northwest Biotherapeutics invested in XXX companies to date.

Northwest Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Northwest Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).